Clinical Trial Update: A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

IDEAYA Biosciences is conducting a Phase 1/2 trial of IDE849 in DLL3-expressing tumors, including small cell lung cancer and neuroendocrine carcinomas, and the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• IDE849 (IDE849)

Snippet

Sponsor: IDEAYA Biosciences | Conditions: Small-cell Lung Cancer, Neuroendocrine Carcinomas | Phase 1, Phase 2 | Status: RECRUITING